Compare NXPL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXPL | CALC |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | NXPL | CALC |
|---|---|---|
| Price | $6.36 | $0.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 24.5K | ★ 296.5K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.46 |
| 52 Week High | $8.37 | $7.20 |
| Indicator | NXPL | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 58.19 |
| Support Level | $0.59 | $0.52 |
| Resistance Level | $7.19 | $0.93 |
| Average True Range (ATR) | 0.90 | 0.12 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 11.98 | 50.12 |
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.